search
Back to results

Immediate Versus Delayed Insertion of Intrauterine Contraception After Medical Abortion (INTRAM)

Primary Purpose

Contraceptive Usage

Status
Recruiting
Phase
Phase 3
Locations
Sweden
Study Type
Interventional
Intervention
Immediate insertion
Sponsored by
Karolinska Institutet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Contraceptive Usage

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years and older,
  • eligible for medical abortion,
  • opting for post abortion IUC,
  • able and willing to comply with planned follow up.

Exclusion Criteria:

  • Contraindication for medical abortion or
  • Contraindication for IUC (contraindications may be present for LNG-IUSs but the woman may still choose a Cu-IUD and thereby enter the study),
  • inability to give informed consent.
  • Septic abortion
  • Known hypersensiblity/allergy to levonorgestrel or any of the substances added to the LNG-IUS
  • Known abnormal uterine cavity
  • Chorioamnionitis
  • Abortion associated bleeding > 1000ml
  • Uterine atony postabortion
  • Placental retention
  • Therapeutic antibiotic treatment during abortion, (antibiotics used only as prophylaxis is accepted)
  • History of breast cancer
  • If any of the following conditions are present an individual evaluation and decision must be done before inclusion: pelvic or genital infection, cervicitis, immunocompromised women, untreated cervical dysplasia, neoplasia in cervix or uterus, acute liver disease or hepatic neoplasia, migraine or other very severe headache, icterus, high uncontrolled blood pressure, serious arterial disease i.e. stroke or myocardial infarction, acute venous thrombosis

Sites / Locations

  • Falun HospitalRecruiting
  • Sahlgrenska HospitalRecruiting
  • Danderyd HospitalRecruiting
  • Karolinska University HospitalRecruiting
  • South General HospitalRecruiting
  • Uppsala Academiska HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Immediate insertion

Standard Insertion

Arm Description

Randomized to insertion within 48 hours of medical abortion

Insertion at 2-4 weeks post medical abortion

Outcomes

Primary Outcome Measures

use of intrauterine contraception at 6 months post abortion
use of intrauterine contraception at 6 months post abortion in both groups evaluated through follow up by telephone/email.

Secondary Outcome Measures

Difference in the proportion of women who successfully have the IUC inserted
• Difference in the proportion of women who successfully have the IUC inserted (success versus failure),
Expulsion rate following insertion in both groups
Expulsion rate during 12 months following insertion in both groups evaluated by telephone/email follow up 12 months post abortion (complete, partial or no expulsion.
Continued use of IUC
• Continued use of IUC at 12 months post insertion evaluated by telephone follow-up (continued use/voluntary discontinued use, involuntary discontinued use including expulsions etc) reasons for discontinuation will be recorded and subsequent use of other contraceptive methods will be noted)
Ease of insertion
Ease of insertion according to health care provider (judged as very easy, moderately-, or very difficult)
Pain at time of insertion assessed as millimeters on a 10cm long unmarked Visual Analogue Scale.
• pain at time of insertion (women will indicate the pain before insertion, at placement of tenaculum, sound and IUC by putting a vertical mark on a 10 cm long horizontal line with a Visual Analogue Scale (VAS) from 0, indicating no pain to 10 indicating worst imaginable pain. Result will be noted in millimeters and entered into case report forms).
Post-abortion bleeding measured as number of days of fresh bleeding
Post-abortion bleeding measured as number of days of uninterrupted fresh bleeding directly following the the abortion.
Post-abortion bleeding measured as number of days of spotting during the first 3 months post abortion
Post-abortion bleeding measured as number of days of spotting- excluding fresh bleeding and menstruation- during the first 3 months after the abortion.
Reasons for non-attempted insertion of IUC
• Reasons for non-attempted insertion of IUC (change of mind, heavy bleeding, not coming for insertion, staff being unavailable etc),
Complications
• Complications (adverse events (AE) and serious AE) bleeding requiring any treatment, uterine perforations and cervical tears, infection requiring treatment with antibiotics, hospitalization for any reason, surgical procedures due to heavy bleeding, incomplete abortions, prolonged bleeding or patient request,
Pregnancies occurring during the 12 month follow-up
• Pregnancies occurring during the 12 month follow-up (planned and unplanned, wanted and unwanted, pregnancy outcomes- ectopic, miscarriage, abortion, molar, kept pregnancy),
proportion of women who would recommend immediate or delayed insertion of IUC post abortion
• proportion of women who would recommend immediate and delayed insertion of IUC by asking women if they would recommend the procedure to a friend (yes/no, asked at the time of insertion and at the 3, 6 and 12 month follow up),
proportion of women who would recommend IUC for post abortion contraception
• Proportion of women who would recommend IUC as post abortion to a friend (yes/no) asked at the time of insertion and at the 3, 6 and 12 month follow up),
The proportion of surgical procedures
• The proportion of surgical procedures in total and for each study site (type of procedure, reasons therefore- infection, retained products of conception, prolonged bleeding etc).

Full Information

First Posted
April 25, 2018
Last Updated
April 28, 2023
Sponsor
Karolinska Institutet
search

1. Study Identification

Unique Protocol Identification Number
NCT03603145
Brief Title
Immediate Versus Delayed Insertion of Intrauterine Contraception After Medical Abortion
Acronym
INTRAM
Official Title
Immediate Versus Delayed Insertion of Intrauterine Contraception at the Time of Medical Abortion- An Open-label, Randomized, Multicenter Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 16, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
PICO: Population: Women with unwanted pregnancy having a medical abortion and fulfilling inclusion and without exclusion criteria and opting for IUC as post abortion contraception. The medical abortion will be carried out according to the Swedish national evidence based guidelines. Intervention: Randomized to insertion of IUC within 48 hours after medical abortion. Control: Randomized to insertion of IUC at the time of a follow-up visit scheduled 2 to 4 weeks after the abortion according to routine care. Objectives: Evaluation of use of IUC, feasibility, safety, compliance, and acceptability of immediate insertion of IUC 0 to 48 hours after medical abortion compared with delayed IUC insertion at 2 to 4 weeks post abortion. The primary outcome measure will be the use of IUC at 6 months in both groups evaluated by telephone calls/emails follow up. Time plan: Planning: -March 2018 Study start: May 2018 End of recruitment: April 2020 Last patient Last visit April 2021 Analysis: 2021 Report of primary outcome and Safety: 2021
Detailed Description
Today 90 percent of terminations of pregnancy are medical abortions. Approximately 33 000 medical abortions are performed in Sweden each year and 20-30 percent of these women opt for IUC as post abortion contraception. Thus, the results of this study potentially affect at least 6600-9900 women every year in Sweden alone. A disadvantage with medical abortion compared with surgical abortion is the standard practice of delayed insertion of IUC. It has been shown that 42 percent of women scheduled for delayed insertion after surgical abortion did not return for the follow up and IUC insertion.(5) This problem is common also in medical abortion practice. Immediate insertion could lead to insertion rates close to 100 percent. However, this practice has not been studied for medical abortion. The background for this trial is the belief that a higher rate of insertion of IUC, perhaps close to 100 percent, within 48 hours after medical abortion, can compensate more than well for a potentially higher rate of expulsion at immediate insertion. A clinically significant difference in IUC use at six months following the medical abortion of at least 20 percent is expected. This large multicenter, randomized, patient centered clinical trial will investigate the effectiveness, feasibility, continued use, safety and acceptability of immediate insertion of intrauterine contraception within 0-48 hours after a completed medical abortion when compared to delayed IUC insertion at 2-4 weeks post abortion which is current practice. Aim To study use, safety and patient acceptability of intrauterine contraception after immediate insertion compared with standard insertion 2-4 weeks post medical abortion at 3, 6 and 12 months post abortion. Drug: Mirena® (LNG-IUS 52mg), Kyleena® (LNG-IUS 19.5mg), Jaydess® (LNG-IUS 13.5 mg), NovaT® (Cu-IUD, medical device, but due to use outside indication it is included in this application) Design: Open label, randomized, controlled, multicenter study. Phase III (therapeutic confirming). Primary objective: To study if immediate insertion of intrauterine contraception is superior to insertion at 2-4 weeks post abortion with regard to number of women using IUC as contraception at 6 months post abortion. Variable: The proportion of women in each group (immediate or delayed) using IUC as contraception at 6 months post abortion (use vs non-use). Secondary objectives: To study if immediate insertion of intrauterine contraception is non-inferior to delayed insertion with regard to safety and acceptability.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Contraceptive Usage

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled open label
Masking
None (Open Label)
Allocation
Randomized
Enrollment
720 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Immediate insertion
Arm Type
Experimental
Arm Description
Randomized to insertion within 48 hours of medical abortion
Arm Title
Standard Insertion
Arm Type
No Intervention
Arm Description
Insertion at 2-4 weeks post medical abortion
Intervention Type
Procedure
Intervention Name(s)
Immediate insertion
Intervention Description
Immediate insertion of intrauterine contraception within 48 hours of medical abortion
Primary Outcome Measure Information:
Title
use of intrauterine contraception at 6 months post abortion
Description
use of intrauterine contraception at 6 months post abortion in both groups evaluated through follow up by telephone/email.
Time Frame
6 months post abortion
Secondary Outcome Measure Information:
Title
Difference in the proportion of women who successfully have the IUC inserted
Description
• Difference in the proportion of women who successfully have the IUC inserted (success versus failure),
Time Frame
10 minutes after (attempted) insertion
Title
Expulsion rate following insertion in both groups
Description
Expulsion rate during 12 months following insertion in both groups evaluated by telephone/email follow up 12 months post abortion (complete, partial or no expulsion.
Time Frame
12 months post insertion
Title
Continued use of IUC
Description
• Continued use of IUC at 12 months post insertion evaluated by telephone follow-up (continued use/voluntary discontinued use, involuntary discontinued use including expulsions etc) reasons for discontinuation will be recorded and subsequent use of other contraceptive methods will be noted)
Time Frame
12 months post abortion
Title
Ease of insertion
Description
Ease of insertion according to health care provider (judged as very easy, moderately-, or very difficult)
Time Frame
10 minutes after (attempted) insertion
Title
Pain at time of insertion assessed as millimeters on a 10cm long unmarked Visual Analogue Scale.
Description
• pain at time of insertion (women will indicate the pain before insertion, at placement of tenaculum, sound and IUC by putting a vertical mark on a 10 cm long horizontal line with a Visual Analogue Scale (VAS) from 0, indicating no pain to 10 indicating worst imaginable pain. Result will be noted in millimeters and entered into case report forms).
Time Frame
10 minutes after (attempted) insertion
Title
Post-abortion bleeding measured as number of days of fresh bleeding
Description
Post-abortion bleeding measured as number of days of uninterrupted fresh bleeding directly following the the abortion.
Time Frame
max 3 months post abortion
Title
Post-abortion bleeding measured as number of days of spotting during the first 3 months post abortion
Description
Post-abortion bleeding measured as number of days of spotting- excluding fresh bleeding and menstruation- during the first 3 months after the abortion.
Time Frame
max 3 months post abortion
Title
Reasons for non-attempted insertion of IUC
Description
• Reasons for non-attempted insertion of IUC (change of mind, heavy bleeding, not coming for insertion, staff being unavailable etc),
Time Frame
within 1 month post abortion
Title
Complications
Description
• Complications (adverse events (AE) and serious AE) bleeding requiring any treatment, uterine perforations and cervical tears, infection requiring treatment with antibiotics, hospitalization for any reason, surgical procedures due to heavy bleeding, incomplete abortions, prolonged bleeding or patient request,
Time Frame
12 months post abortion
Title
Pregnancies occurring during the 12 month follow-up
Description
• Pregnancies occurring during the 12 month follow-up (planned and unplanned, wanted and unwanted, pregnancy outcomes- ectopic, miscarriage, abortion, molar, kept pregnancy),
Time Frame
12 months post abortion
Title
proportion of women who would recommend immediate or delayed insertion of IUC post abortion
Description
• proportion of women who would recommend immediate and delayed insertion of IUC by asking women if they would recommend the procedure to a friend (yes/no, asked at the time of insertion and at the 3, 6 and 12 month follow up),
Time Frame
12 months post abortion
Title
proportion of women who would recommend IUC for post abortion contraception
Description
• Proportion of women who would recommend IUC as post abortion to a friend (yes/no) asked at the time of insertion and at the 3, 6 and 12 month follow up),
Time Frame
12 months post abortion
Title
The proportion of surgical procedures
Description
• The proportion of surgical procedures in total and for each study site (type of procedure, reasons therefore- infection, retained products of conception, prolonged bleeding etc).
Time Frame
3 months post abortion

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years and older, eligible for medical abortion, opting for post abortion IUC, able and willing to comply with planned follow up. Exclusion Criteria: Contraindication for medical abortion or Contraindication for IUC (contraindications may be present for LNG-IUSs but the woman may still choose a Cu-IUD and thereby enter the study), inability to give informed consent. Septic abortion Known hypersensiblity/allergy to levonorgestrel or any of the substances added to the LNG-IUS Known abnormal uterine cavity Chorioamnionitis Abortion associated bleeding > 1000ml Uterine atony postabortion Placental retention Therapeutic antibiotic treatment during abortion, (antibiotics used only as prophylaxis is accepted) History of breast cancer If any of the following conditions are present an individual evaluation and decision must be done before inclusion: pelvic or genital infection, cervicitis, immunocompromised women, untreated cervical dysplasia, neoplasia in cervix or uterus, acute liver disease or hepatic neoplasia, migraine or other very severe headache, icterus, high uncontrolled blood pressure, serious arterial disease i.e. stroke or myocardial infarction, acute venous thrombosis
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Helena Kopp Kallner, MD, PhD
Phone
+46704402070
Email
helena.kopp-kallner@ki.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helena Kopp Kallner, MD, PhD
Organizational Affiliation
Karolinska Institute, danderyd Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Falun Hospital
City
Falun
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sara Hogmark, MD
Facility Name
Sahlgrenska Hospital
City
Gothenburg
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helena Hognert, MD, PhD
Facility Name
Danderyd Hospital
City
Stockholm
ZIP/Postal Code
182 88
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helena Kopp Kallner, MD, PhD
Facility Name
Karolinska University Hospital
City
Stockholm
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kristina Gemzell Danielsson, MD, PhD
Facility Name
South General Hospital
City
Stockholm
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cecilia Berger, MD, PhD
Facility Name
Uppsala Academiska Hospital
City
Uppsala
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emma Håstad, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Immediate Versus Delayed Insertion of Intrauterine Contraception After Medical Abortion

We'll reach out to this number within 24 hrs